Business
LIPOCINE GRANTED US PATENTS DIRECTED TO CNS AND LIVER PROGRAMS
SALT LAKE CITY, June 14, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on neuroendocrine and metabolic disorders,
About this update from Lipocine Inc.
[{"type":"text","content":"SALT LAKE CITY, June 14, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on neuroendocrine and metabolic disorders, today announced that the United States Patent and Trademark Office (USPTO) has granted US patent 11,337,987 for \"Compositions and Methods for Treating Central Nervous System (CNS) Disorders\" and US patent 11,370,811 for \"Testosterone Dodecanoate Compositions and Methods of Preparation and Use\". \n\n \n \n \n \n \n \n\n \n\"We are pleased to have new patents granted in support of our innovative programs to treat liver and CNS disorders,\" said Dr. Mahesh Patel, Chairman, President, and CEO of Lipocine.\nAbout LipocineLipocine Inc. is a biopharmaceutical company focused on neuroendocrine and metabolic disorders using its proprietary drug delivery technologies. Lipocine's clinical development pipeline includes: TLANDO, LPCN 1144, TLANDO XR, LPCN 1148 and LPCN 1107. TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate, has received tentative approval from the FDA for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism, in adult males. LPCN 1144, an oral product of bioidentical testosterone, recently completed a proof-of-concept clinical study demonstrating the potential utility in the treatment of non-cirrhotic NASH. LPCN 1144 is currently being studied in a Phase 2 clinical study. TLANDO XR, a novel oral prodrug of testosterone, originated and is being developed by Lipocine as a next-generation oral testosterone product with potential for once-daily dosing. In a phase 2 clinical evaluation when administered as once daily or twice daily TLANDO XR met the typical primary and secondary end points. LPCN 1148 is an oral prodrug of bioidentical testosterone targeted for the treatment of cirrhosis. LPCN 1107 is potentially the first oral hydroxyprogesterone caproate product candidate indicated for the prevention of recurrent preterm birth and has been granted orphan drug designation by the FDA. For more information. For more information, please visit www.lipocine.com.\nForward-Looking StatementsThis release contains \"forward-looking statements\" that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include statements that are not historical facts regardi...